David Scadden

David T.
Scadden is the founder of Fate Therapeutics, Inc., founded in 2007.
Dr. Scadden was the founder of The Massachusetts General Hospital, founded in 2003, where the title held was Director-Hematologic Malignancies Center.
Dr. Scadden is the founder of Harvard Stem Cell Institute, founded in 2004, holding the title of Director.
Dr. Scadden was the founder of Magenta Therapeutics, Inc., founded in 2015, where the title held was Independent Director.
Dr. Scadden is also the founder of Stratus Therapeutics, Inc.,The General Hospital Corp.,Clear Creek Bio, Inc...
Dr. Scadden currently holds the position of Chairman-Emeritus & Professor at Harvard University since 2006.
Dr. Scadden is Chairman-Emeritus & Professor at Harvard Medical School.
Dr. Scadden is an Independent Director at Agios Pharmaceuticals, Inc. since 2017.
Dr. Scadden is a Director at Lightning Biotherapeutics, Inc. Dr. Scadden is an Independent Director at Editas Medicine, Inc. since 2019.
Dr. Scadden is a Director at Red Oak Medicines, Inc. Dr. Scadden is a Director at Lifevault Bio.
Dr. Scadden is a Director at Sonata Therapeutics, Inc. Dr. Scadden is an Associate Member at Massachusetts Institute of Technology.
Dr. Scadden is a Member of the American Academy of Arts & Sciences.
Dr. Scadden is a Member of the National Academy of Medicine (United States).
Dr. Scadden is an Associate Member at The Broad Institute, Inc. Former positions include Director at The International Society for Stem Cell Research.
Dr. Scadden was Independent Director at Carisma Therapeutics, Inc. from 2024 to 2025.
Dr. Scadden was Member-Scientific Counselors Board at National Cancer Institute.
Dr. Scadden was Member-External Experts Board at National Heart, Lung & Blood Institute.
Education includes undergraduate degree from Bucknell University, doctorate degrees from Case Western Reserve University and the University of Lund.